Unverified50% confidenceFactExact time
Clinical trials of most GLP-1 drugs did not include eating disorder patients in their primary endpoints, meaning safety data for the drugs in this population are limited.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/30/2026
First Seen
Valid until: 1/28/2027
Sources
Related Entities
Related Claims
UnverifiedIncluding eating disorder-related symptoms in the pharmacovigilance scope of GLP-1 drugs means embedding psychological assessment into prescribing, follow-up, and data reporting.73% similarUnverifiedThe conversion rate from candidate biomarkers to approved clinical tests is extremely low, and a large number of research results cannot be reproduced.70% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1115049API
curl https://kongchang.com/api/v1/knowledge/claims/1115049MCP
get_claim(id=1115049)